首页> 外文期刊>JAMA: the Journal of the American Medical Association >Low-dose aspirin use and performance of immunochemical fecal occult blood tests.
【24h】

Low-dose aspirin use and performance of immunochemical fecal occult blood tests.

机译:小剂量阿司匹林的使用和免疫化学性粪便潜血测试的性能。

获取原文
获取原文并翻译 | 示例
           

摘要

CONTEXT: Immunochemical fecal occult blood tests (iFOBTs) are potentially promising tools for colorectal cancer screening. Low-dose aspirin use, which increases the likelihood of gastrointestinal bleeding, is common in the target population for colorectal cancer screening. OBJECTIVE: To assess the association of low-dose aspirin use with the performance of 2 quantitative iFOBTs in a large sample of patients undergoing colorectal cancer screening. DESIGN, SETTING, AND PARTICIPANTS: Diagnostic study conducted from 2005 through 2009 at internal medicine and gastroenterology practices in southern Germany including 1979 patients (mean age, 62.1 years): 233 regular users of low-dose aspirin (167 men, 67 women) and 1746 who never used low-dose aspirin (809 men, 937 women). MAIN OUTCOME MEASURES: Sensitivity, specificity, positive and negative predictive values, and area under receiver operating characteristic (ROC) curves in detecting advanced colorectal neoplasms (colorectal cancer or advanced adenoma) with 2 quantitative iFOBTs. RESULTS: Advanced neoplasms were found in 24 users (10.3%) and 181 nonusers (10.4%) of low-dose aspirin. At the cut point recommended by the manufacturer, sensitivities of the 2 tests were 70.8% (95% confidence interval [CI], 48.9%-87.4%) for users compared with 35.9% (95% CI, 28.9%-43.4%) for nonusers and 58.3% (95% CI, 36.6%-77.9%) for users compared with 32.0% (95% CI, 25.3%-39.4%) for nonusers (P = .001 and P = .01, respectively). Specificities were 85.7% (95% CI, 80.2%-90.1%) for users compared with 89.2% (95% CI, 87.6%-90.7%) for nonusers and 85.7% (95% CI, 80.2%-90.1%) for users compared with 91.1% (95% CI, 89.5%-92.4%) for nonusers (P = .13 and P = .01, respectively). The areas under the ROC curve were 0.79 (95% CI, 0.68-0.90) for users compared with 0.67 (95% CI, 0.62-0.71) for nonusers and 0.73 (95% CI, 0.62-0.85) for users compared with 0.65 (95% CI, 0.61-0.69) for nonusers (P = .05 and P = .17, respectively). Among men, who composed the majority of low-dose aspirin users, the areas under the ROC curve were 0.87 (95% CI, 0.76-0.98) for users compared with 0.68 (95% CI, 0.63-0.74) for nonusers and 0.81 (95% CI, 0.68-0.93) for users compared with 0.67 (95% CI, 0.61-0.72) for nonusers (P = .003 and P = .04, respectively). CONCLUSION: For 2 iFOBTs, use of low-dose aspirin compared with no aspirin was associated with a markedly higher sensitivity for detecting advanced colorectal neoplasms, with only a slightly lower specificity.
机译:上下文:免疫化学粪便潜血测试(iFOBTs)是用于结肠直肠癌筛查的潜在有前途的工具。低剂量阿司匹林的使用会增加胃肠道出血的可能性,在大肠癌筛查的目标人群中很常见。目的:评估在接受大肠癌筛查的大量患者中,低剂量阿司匹林的使用与2种定量iFOBTs的相关性。设计,地点和参与者:从2005年至2009年对德国南部的内科和胃肠病学实践进行的诊断研究,包括1979例患者(平均年龄,62.1岁):233例低剂量阿司匹林的常规使用者(167名男性,67名女性) 1746年从未使用过小剂量阿司匹林的男性(809名男性,937名女性)。主要观察指标:用2种定量iFOBT检测晚期结直肠肿瘤(结直肠癌或晚期腺瘤)时的敏感性,特异性,阳性和阴性预测值以及接受者操作特征(ROC)曲线下面积。结果:在低剂量阿司匹林的24位使用者(10.3%)和181位非使用者(10.4%)中发现了晚期肿瘤。在制造商建议的临界点,用户的2种测试的灵敏度为70.8%(95%置信区间[CI],48.9%-87.4%),而对于用户,灵敏度为35.9%(95%CI,28.9%-43.4%)。非使用者使用者则为58.3%(95%CI,36.6%-77.9%),而非使用者则为32.0%(95%CI,25.3%-39.4%)(分别为P = .001和P = .01)。用户的特异性为85.7%(95%CI,80.2%-90.1%),而非用户为89.2%(95%CI,87.6%-90.7%)和85.7%(95%CI,80.2%-90.1%)非使用者则为91.1%(95%CI,89.5%-92.4%)(分别为P = .13和P = .01)。用户的ROC曲线下面积为0.79(95%CI,0.68-0.90),非用户为0.67(95%CI,0.62-0.71),用户为0.73(95%CI,0.62-0.85),而用户为0.65(95%CI,0.62-0.85)。非使用者(分别为P = 0.05和P = .17)的95%CI,0.61-0.69)。在占低剂量阿司匹林使用者最多的男性中,ROC曲线下使用者的面积为0.87(95%CI,0.76-0.98),而非使用者为0.68(95%CI,0.63-0.74)和0.81(用户的95%CI,0.68-0.93),而非用户则为0.67(95%CI,0.61-0.72)(分别为P = .003和P = .04)。结论:对于2种iFOBT,使用低剂量阿司匹林与不使用阿司匹林相比,用于检测晚期大肠肿瘤的灵敏度明显更高,但特异性稍低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号